相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
Raymond S. Turner et al.
ANNALS OF NEUROLOGY (2020)
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease A Phase 2 Randomized Clinical Trial
Fernando. L. Pagan et al.
JAMA NEUROLOGY (2020)
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases
Alan J. Fowler et al.
HUMAN MOLECULAR GENETICS (2020)
Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease Reply
Charbel Moussa
JAMA NEUROLOGY (2020)
18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer
Manoj Kumar et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
Alan J. Fowler et al.
DRUGS IN R&D (2019)
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model
Michal Wegrzynowici et al.
ACTA NEUROPATHOLOGICA (2019)
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
Fernando L. Pagan et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Inhibition of DDR1-BCR signalling by nilotinib asanew therapeutic strategy for metastatic colorectal cancer
Maya Jeitany et al.
EMBO MOLECULAR MEDICINE (2018)
Tau clearance improves astrocytic function and brain glutamate-glutamine cycle
Michaeline L. Hebron et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2018)
Predictors of clinically meaningful change in PDQ-39 in Parkinson's disease
Adam Margolius et al.
PARKINSONISM & RELATED DISORDERS (2018)
Mechanism of neurotransmitter release coming into focus
Josep Rizo
PROTEIN SCIENCE (2018)
Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models
Michaeline Hebron et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
The influence of cell membrane and SNAP25 linker loop on the dynamics and unzipping of SNARE complex
Yi Shi et al.
PLOS ONE (2017)
Tyrosine kinase inhibition reverses TDP-43 effects on synaptic protein expression, astrocytic function and amino acid dis-homeostasis
Lanier Heyburn et al.
JOURNAL OF NEUROCHEMISTRY (2016)
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Clifford R. Jack et al.
NEUROLOGY (2016)
Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies
Fernando Pagan et al.
JOURNAL OF PARKINSONS DISEASE (2016)
NILOTINIB AND BOSUTINIB MODULATE PRE-PLAQUE ALTERATIONS OF BLOOD IMMUNE MARKERS AND NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE MODELS
I. Lonskaya et al.
NEUROSCIENCE (2015)
Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance
Irina Lonskaya et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
Irina Lonskaya et al.
MOLECULAR NEURODEGENERATION (2014)
Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
Irina Lonskaya et al.
EMBO MOLECULAR MEDICINE (2013)
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinsons disease models
Michaeline L. Hebron et al.
HUMAN MOLECULAR GENETICS (2013)
Parkin Ubiquitinates Tar-DNA Binding Protein-43 (TDP-43) and Promotes Its Cytosolic Accumulation via Interaction with Histone Deacetylase 6 (HDAC6)
Michaeline L. Hebron et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons
Tomasz Skorski
CHEMISTRY & BIOLOGY (2011)
Extended kinase profile and properties of the protein kinase inhibitor nilotinib
Paul W. Manley et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Vps-C complexes: gatekeepers of endolysosomal traffic
Daniel P. Nickerson et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Francois-Xavier Mahon et al.
CANCER RESEARCH (2008)
Nilotinib: A Second-Generation Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia
David L. DeRemer et al.
CLINICAL THERAPEUTICS (2008)
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib
Elizabeth Day et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Unequal group sizes in randomised trials: guarding against guessing
KF Schulz et al.
LANCET (2002)
分享论文
